Newsfeeds - Spark Newswire

1 minute read

Cantor Fitzgerald Initiates Coverage On SELLAS Life Sciences Gr with Overweight Rating, Announces Price Target of $18

Today, 3:45 AM

Cantor Fitzgerald initiates coverage on SELLAS Life Sciences Gr (NASDAQ:SLS) with a Overweight rating and announces Price Target of $18.

SLS

1 minute read

News

SELLAS Life Sciences Group 8K Shows Co. Had $32M In Cash, Cash Equivalents, 15.8M Shares Of Common Stock Outstanding; Says Including 421K Shares Sold To Co.’s Controlled Equity Offering Sales Agreement With Cantor Fitzgerald, Priced At $13.15/Share

By Michael Horton

Today, 3:45 AM

-SEC Filing

SLS

5 minute read

58 Biggest Movers From Yesterday

By Lisa Levin

Today, 3:45 AM

Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share.

ABOS

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

Today, 3:45 AM

Gainers

ALGS

6 minute read

72 Biggest Movers From Yesterday

By Lisa Levin

Today, 3:45 AM

Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share.

ALT

2 minute read

Sellas Life Sciences Breaks Out Of Pennant Pattern: Technical Levels To Watch

By Tyler Bundy

Today, 3:45 AM

SELLAS Life Sciences Group Inc. (NASDAQ: SLS) shares were trading lower Wednesday after the company released updated clinical and initial

SLS

2 minute read

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 3:45 AM

ALT

1 minute read

Sellas Life Sciences Reports Encouraging Immune Response From GPS Combo Trial In Ovarian Cancer

By Vandana Singh

Today, 3:45 AM

Sellas Life Sciences Group Inc (NASDAQ:SLS) has announced updated data and initial immunobiological data from its Phase 1/2 evaluating its lead…

MRK

4 minute read

SELLAS Reports Updated Clinical Data From Phase 1/2 Study Of Galinpepimut-S Combined With Keytruda Showing 100% Of Patients Alive And 45.5 Percent Continuing Investigational Therapy As Of The Latest Follow-Up

By Bill Haddad

Today, 3:45 AM

Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS Induced WT1-Specific Immune

SLS

4 minute read

45 Biggest Movers From Yesterday

By Lisa Levin

Today, 3:45 AM

Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares surged 44.8% to close at $6.50 on Wednesday after the company reported topline Phase 2 bone mineral density data for EB613.

ACST